Promising targets and drugs in development for colorectal cancer

Seminars in Oncology

Volumn 38, Issue 4, 2011, Pages 588-597

  Thompson, Chris ^a   Leong, Stephen ^a   Messersmith, Wells ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AFATINIB; AGO 14699; AXL 1717; AZD 8055; BGT 226; BMK 120; BMS 754807; BS 1201; CAL 101; CEP 9722; CETUXIMAB; CIXUTUMUMAB; CONATUMUMAB; E 6201; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; FOLINIC ACID; GA 201; GANITUMAB; GSK 1059615; GSK 1120212; GSK 2118436; GSK 2141795; INO 1001; IPI 926; IRINOTECAN; KRX 401; LDE 225; LENALIDOMIDE; LINSITINIB; LONAFARNIB; MEK 162; MITOGEN ACTIVATED PROTEIN KINASE; MK 0752; MK 2206; MK 4827; MONOCLONAL ANTIBODY; MSC 1936369B; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NECITUMUMAB; NIMUTUZUMAB; OLAPARIB; OS 1027; OXALIPLATIN; PALOMID 529; PANITUMUMAB; PERIFOSINE; PF 03084014; PF 04449913; PF 04691502; PLX 3603; REGN 421; RIDAFOROLIMUS; RO 4929097; RO 5083945; ROBATUMUMAB; SELUMETINIB; SR 13668; SYM 004; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VEMURAFENIB; VISMODEGIB; VQD 002; XL 139; XL 147; XL 281; XL 418; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

APOPTOSIS; ARTHRALGIA; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENETIC TRANSCRIPTION; HUMAN; KERATOACANTHOMA; LIGAND BINDING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 79960987682     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.05.013     Document Type: Article

References (88)

1. Cancer facts and figures 2010. 2010. Accessed August 30, 2010, at http://www.cancer.gov.
2. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999;35:1343-7. (Pubitemid 29397434)
3. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC) [abstract]. J Clin Oncol (Meeting Abstracts). 2007;25:4030.
4. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 1999;35:1338-42. (Pubitemid 29397433)
5. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217-23. (Pubitemid 47548561)
6. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
7. Siena S, Tabernero J, Cunningham D, et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3566.
8. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
9. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990;265:7709-12. (Pubitemid 20158927)
10. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16:102-8. (Pubitemid 40124486)
11. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010;29:3033-43.
12. Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;65:8-20. (Pubitemid 350216479)
13. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
14. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-71.
15. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64. (Pubitemid 46797944)
16. Barton S, Starling N, Swanton C. Predictive molecular markers of response to epidermal growth factor receptor (EGFR) family-targeted therapies. Curr Cancer Drug Targets. 2010;8:799-812.
17. Gravalos C, Cassinello J, Fernandez-Ranada I, Holgado E. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2007;6:691-9. (Pubitemid 350221366)
18. Macarulla T, Markman B, Tabernero J. Membrane receptors as targets for therapeutic approaches in colorectal cancer. In: Govindan R, editor. ASCO 2010 Educational Book; 2010 June 4-8, 2010. Chicago: Joy Curzio; 2010:E52-5.
19. Clinical Trial Database. 2010. Accessed September 2, 2010, at http://www.clinicaltrials.gov.
20. Markman B, Gomez-Roca C, Cervantes-Ruiperez A, et al. Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC) [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:2522.
21. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650-7.
22. Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother. 2011;1:61-73.
23. Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010;70:588-97.
24. Schaefer GM. Targeting EGFR and HER3 with a "two-inone antibody". In: AACR 101st Annual Meeting; 2010 April 18, 2010; Washington, DC; 2010.
25. Trarbach T, Moehler M, Heinemann V, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer. 2010;102:506-12.
26. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002;62:5800-6. (Pubitemid 35204738)
27. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2007;25:3534.
28. Saltz L, Infante J, Schwartzberg L, et al. Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol (Meeting Abstracts). 2009;27:4079.
29. Chawla SP, Tabernero J, Kindler HL, et al. Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3102.
30. Eng C, Tabernero J, Nowara E, et al. Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): updated safety results [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:e14083.
31. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol. 2009;15:5141-8.
32. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulinlike growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94:972-80. (Pubitemid 34814726)
33. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 1999;30:1128-33. (Pubitemid 29480878)
34. Donovan EA, Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol. 2008;66:91-8. (Pubitemid 351446110)
35. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002;3:298-302. (Pubitemid 34546447)
36. Hopkins A, Crowe PJ, Yang JL. Effect of type 1 insulinlike growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol. 2010;136:639-50.
37. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2008;26:3519.
38. Higano CS, Yu EY, Whiting SH, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2007;25:3505.
39. Lindsay CR, Chan E, Evans TR, et al. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2009;27:2559.
40. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27:5800-7.
41. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:7500.
42. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9.
43. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293-7.
44. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res. 2010;16:2921-6.
45. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004;22:3950-7. (Pubitemid 41079877)
46. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459-64. (Pubitemid 27232866)
47. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12.
48. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699-731.
49. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3570.
50. Flaherty K, Puzanov I, Kim K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.
51. Lacouture ME, McArthur GA, Chapman PB, et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:8592.
52. Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3534.
53. Avruch J. MAP kinase pathways: the first twenty years. Biochim Biophys Acta. 2007;1773:1150-60. (Pubitemid 47125973)
54. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456-62. (Pubitemid 41185111)
55. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16:1924-37.
56. Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs. 2010:1-8.
57. Borad MJ, Akerele CE, Ramanathan RK, et al. Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:2505.
58. Delord J, Houede N, Awada A, et al. First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:2504.
59. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:2503.
60. McCubrey JA, Steelman LS, Abrams SL, et al. Emerging MEK inhibitors. Expert Opin Emerging Drugs. 2010;15:203-23.
61. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69:565-72.
62. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010;16:3811-8.
63. Leong S, Messersmith WA, Tan AC, Eckhardt SG. Novel agents in the treatment of metastatic colorectal cancer. Cancer J. 2010;16:273-82.
64. Baselga J, De Jonge MJ, Rodon J, et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3003.
65. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3005.
66. Edelman G, Bedell C, Shapiro G, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3004.
67. Keryx receives FDA fast track designation for KRX-0401 (Perifosine) for the treatment of refractory advanced colorectal cancer. Accessed September 7, 2010, at http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol- newsArticle&ID=1409446&highlight=.
68. Richards DA, Nemunaitis JJ, Vukelja SJ, et al. Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3531.
69. He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin. 2010;31:1172-80.
70. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-34.
71. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7:153-62.
72. Vilar Sanchez E, Chow A, Raskin L, Iniesta MD, Mukherjee B, Gruber SB. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer [abstract]. J Clin Oncol (Meeting Abstracts). 2009;27:11028.
73. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5:1026-33. (Pubitemid 44835129)
74. Merchant AA, Matsui W. Targeting Hedgehog - a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130-40.
75. Bian YH, Huang SH, Yang L, Ma XL, Xie JW, Zhang HW. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J Gastroenterol. 2007;13:1659-65. (Pubitemid 46711335)
76. Yoshikawa K, Shimada M, Miyamoto H, et al. Sonic hedgehog relates to colorectal carcinogenesis. J Gastroenterol. 2009;44:1113-7.
77. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res. 2009;69:6007-10.
78. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164-72.
79. Bendell JC, Hart LL, Firdaus I, et al. Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:3530.
80. Curis announces Genentech's phase II clinical trial results of GDC-0449 in combination with Avastin(R) and chemotherapy in first-line metastatic colorectal cancer. 2010. Accessed September 8, 2010, at http://phx.corporate-ir. net/phoenix.zhtml?c=123198&p=irolnewsArticle&ID=1438731&highlight=.
81. Rodon Ahnert J, Baselga J, et al. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:2500.
82. Siu LL, Papadopoulos K, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28:2501.
83. Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010;80:690-701.
84. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269-71. (Pubitemid 39336870)
85. Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol. 2004;167:215-21. (Pubitemid 39435065)
86. Meng RD, Shelton CC, Li YM, et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69:573-82.
87. Reedijk M, Odorcic S, Zhang H, et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol. 2008;33:1223-9.
88. Tolcher AW, Mikulski SM, Messersmith WA, et al. A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors [abstract]. J Clin Oncol (Meeting Abstracts) 2010;28:2502.